MD Anderson launches Phase 1/2 trial of TROP2‑targeted CAR‑NK therapy combined with cetuximab for peritoneal metastasis of colorectal cancer
Limitations of Peritoneal Metastasis in Colorectal Cancer and Rationale for a New Therapy
Peritoneal metastases, observed in approximately 8–15% of patients with colorectal cancer, are associated with a very poor prognosis because the physical barrier of the peritoneal cavity and poor vascularization limit the delivery of conventional chemotherapeutic agents to tumor sites. The median overall survival with the current standard of care—combination chemotherapy and targeted antibodies—is only 5–16 months, and surgical resection together with hyperthermic intraperitoneal chemotherapy (HIPEC) is applicable to a very limited patient population. Accordingly, the MD Anderson Cancer Center has initiated an innovative Phase 1/2 trial combining an intraperitoneal and intravenous administration of a TROP2‑targeted CAR‑NK cell therapy.
Mechanism of Action: TROP2 Targeting and TGFBR2 Knockout
The CAR‑NK product used in this trial targets the trophoblast cell surface antigen 2 (TROP2) protein, which is overexpressed on the surface of colorectal and other solid tumors, enabling selective tumor cell killing. To overcome the potent immunosuppressive TGF‑β signaling within the tumor microenvironment, the construct incorporates a CRISPR‑mediated knockout of the TGF‑β receptor 2 (TGFBR2) gene and also includes an IL‑15 transgene. In addition, co‑administration of the epidermal growth factor receptor (EGFR) inhibitor cetuximab (trade name Erbitux) is intended to amplify NK‑cell cytotoxicity through antibody‑dependent cellular cytotoxicity (ADCC) synergy.
Chip‑CRC Phase 1/2 Study Design and Evaluation
The trial (NCT07411599, study name Chip‑CRC) began patient enrollment on 20 April 2026, with a primary completion date of 15 November 2028 and an estimated study completion in November 2030. In Phase 1, intraperitoneal and intravenous dosing will be administered concurrently to assess safety and dose‑limiting toxicities (DLT) and to establish the maximum tolerated dose (MTD). Phase 2 will evaluate efficacy at the selected dose by measuring objective response rate (ORR) of peritoneal lesions and progression‑free survival (PFS).
Market Size and Competitive Landscape for Refractory Peritoneal Metastasis
The global metastatic colorectal cancer (mCRC) market is estimated at $6.78 billion to $7.68 billion for 2024–2025 and is projected to expand to roughly $19 billion by 2035. Peritoneal metastasis carries a dismal 5‑year survival rate of only 6%, indicating a substantial unmet need; however, the TROP2‑targeted cell therapy space remains in early development with no approved products. If the MD Anderson combination trial proves successful, it could establish a new standard in solid‑tumor cell therapy by integrating with the cetuximab regimen currently dominated by Eli Lilly and Merck KGaA.
This Phase 1/2 trial addresses the unmet need in refractory colorectal cancer peritoneal metastasis, where the 5‑year survival rate is only 6%, by seeking to overcome the limitations of systemic chemotherapy and to open a novel target segment within the roughly $7.6 billion metastatic colorectal cancer market. From an investor perspective, combining the already commercialized antibody therapy cetuximab mitigates clinical risk while providing a milestone to validate the utility of TGFBR2 knockout technology for overcoming immunosuppressive TGF‑β signaling. For investigators and industry stakeholders, the dual‑route safety data from concurrent intraperitoneal and intravenous administration will furnish key design parameters for future TROP2‑expressing solid‑tumor cell‑therapy platforms. In the short term, the priority is to define a tolerable dose through toxicity assessment; in the medium to long term, demonstrating a progression‑free survival advantage over existing surgical approaches (CRS + HIPEC) will be pivotal for accelerating regulatory approval.
Source: ClinicalTrials.gov (api_ct)